| Efficacy of prothrombin complex concentrate to reverse the anticoagulant effect of the pentasaccharide fondaparinux in a rabbit model. | |
| | |
MedLine Citation:
|
PMID: 20941458 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
As a potent anticoagulant agent, fondaparinux exposes a risk of bleeding. An effective way to reverse its effects is needed. It was the objective to study efficacy and safety of prothrombin complex concentrate (PCC) to reverse the anticoagulant effect of fondaparinux in a rabbit model of bleeding and thrombosis. In anaesthetised and ventilated rabbits, the Folts model was applied: a stenosis (75%) and an injury were carried out on the carotid artery, inducing thrombosis. Blood flow decreased as thrombus size increased until the pressure gradient was such that the thrombus was released and local blood flow was suddenly restored. This is known as a cyclic flow reduction (CFR). After the first CFR, rabbits were randomised into three groups: control (saline and saline after 1 minute), fondaparinux (fondaparinux [3 mg.kg-1] and saline), PCC (fondaparinux and PCC [40 UI.kg-1]). Then CFRs were recorded over 20 minutes. The following were measured: ear immersion bleeding time (BT), haemoglobin blood level (Hb1) and thrombelastometric parameters (ROTEM®). Finally, a hepatosplenic section was performed; 15 minutes later, the amount of blood loss was recorded as primary endpoint and Hb2 was measured. Blood loss was increased with fondaparinux and normalised with PCC. Regarding ROTEM® INTEM, fondaparinux increased clotting time and clotting formation time. PCC normalised these parameters. EXTEM and FIBTEM tests were not modified. Regarding safety, PCC did not increase CFRs. PCC reduced bleeding without increasing thrombosis and was effective to reverse the haemorrhagic effect of fondaparinux in this rabbit model. |
| | |
Authors:
|
Anne Godier; Marion Durand; Joseph Emmerich; Blandine Dizier; Thomas Lecompte; Charles-Marc Samama |
Related Documents
:
|
22588188 - No evidence for additional blood-brain barrier p-glycoprotein dysfunction in alzheimer'... 7382058 - The effects of bicarbonate on blood coagulation. 7926688 - Activation of blood clotting factors by microbial proteinases. 9568658 - Can ringer's lactate be used safely with blood transfusions? 8264888 - Difluoromethylornithine decreases postischemic brain edema and blood-brain barrier brea... 11178418 - detection of pyrogens using human whole blood |
Publication Detail:
|
Type: Journal Article Date: 2010-10-12 |
Journal Detail:
|
Title: Thrombosis and haemostasis Volume: 105 ISSN: 0340-6245 ISO Abbreviation: Thromb. Haemost. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-01-04 Completed Date: 2011-05-18 Revised Date: 2011-05-23 |
Medline Journal Info:
|
Nlm Unique ID: 7608063 Medline TA: Thromb Haemost Country: Germany |
Other Details:
|
Languages: eng Pagination: 161-8 Citation Subset: IM |
Affiliation:
|
Department of Anesthesia and Critical Care, Paris Descartes University; Hôtel-Dieu, Paris, France. anne.godier@htd.aphp.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anticoagulants / pharmacology Blood Coagulation Factors / adverse effects, pharmacology*, therapeutic use Carotid Arteries Disease Models, Animal Hemorrhage / chemically induced Polysaccharides / adverse effects, pharmacology*, therapeutic use Rabbits Regional Blood Flow Thrombosis / drug therapy* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Blood Coagulation Factors; 0/Polysaccharides; 0/fondaparinux; 37224-63-8/prothrombin complex concentrates |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Next Document: Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.